26. Systemic Lupus Erythematosus

  1. John T. Queenan MD2,
  2. Catherine Y. Spong MD3 and
  3. Charles J. Lockwood MD4
  1. Christina S. Han MD and
  2. Edmund F. Funai MD

Published Online: 4 JAN 2012

DOI: 10.1002/9781119963783.ch26

Queenan's Management of High-Risk Pregnancy: An Evidence-Based Approach, Sixth Edition

Queenan's Management of High-Risk Pregnancy: An Evidence-Based Approach, Sixth Edition

How to Cite

Han, C. S. and Funai, E. F. (2012) Systemic Lupus Erythematosus, in Queenan's Management of High-Risk Pregnancy: An Evidence-Based Approach, Sixth Edition (eds J. T. Queenan, C. Y. Spong and C. J. Lockwood), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781119963783.ch26

Editor Information

  1. 2

    Department of Obstetrics and Gynecology, Georgetown University School of Medicine, Washington, DC, USA

  2. 3

    Bethesda, MD, USA

  3. 4

    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA

Author Information

  1. Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA

Publication History

  1. Published Online: 4 JAN 2012
  2. Published Print: 24 FEB 2012

ISBN Information

Print ISBN: 9780470655764

Online ISBN: 9781119963783

SEARCH

Keywords:

  • SLE, and systemic manifestations, arthralgias, rashes, neurologic;
  • SLE, chronic autoimmune disorder, flares, remissions;
  • shift in cytokines, Th1 to a Th2 pattern in pregnancy;
  • lifetime risk of women developing SLE, 1 in 700;
  • SLE etiology, multifactorial;
  • hormonal, environmental factors and disease process;
  • criteria for diagnosis of SLE;
  • anti-dsDNA and anti-Sm, specific for lupus;
  • SLE effect on multiple organ systems;
  • SLE in pregnancy, affecting mother and fetus

Summary

Systemic lupus erythematosus is a chronic autoimmune disorder characterized by periods of disease flares and remissions. It is a heterogeneous disorder with a variety of clinical and laboratory manifestations. Affected patients can have a relatively benign course, affecting only the skin and musculoskeletal system, or be affected by aggressive, life-threatening visceral involvement. Systemic manifestations include arthralgias, rashes, renal abnormalities, neurologic complications, thromboemboli, myocarditis, and serositis.